C
C. Cecchetti
Researcher at Vita-Salute San Raffaele University
Publications - 11
Citations - 187
C. Cecchetti is an academic researcher from Vita-Salute San Raffaele University. The author has contributed to research in topics: Diffuse large B-cell lymphoma & Lenalidomide. The author has an hindex of 5, co-authored 11 publications receiving 111 citations.
Papers
More filters
Journal ArticleDOI
Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma
Tarec Christoffer El-Galaly,Chan Yoon Cheah,Mette Dahl Bendtsen,Grzegorz S. Nowakowski,Roopesh Kansara,Kerry J. Savage,Joseph M. Connors,Laurie H. Sehn,Neta Goldschmidt,Adir Shaulov,Umar Farooq,Brian K. Link,Andrés J.M. Ferreri,Teresa Calimeri,C. Cecchetti,Eldad J. Dann,Carrie A. Thompson,Tsofia Inbar,Matthew J. Maurer,Inger Lise Gade,Maja Bech Juul,Jakob Werner Hansen,Staffan Holmberg,Thomas Stauffer Larsen,Sabrina Cordua,N. George Mikhaeel,Martin Hutchings,John F. Seymour,Michael Roost Clausen,Daniel J. Smith,Stephen Opat,Michael Gilbertson,Gita Thanarajasingam,Diego Villa +33 more
TL;DR: In this large international cohort of patients treated with first-line immunochemotherapy, outcomes following SCNS remain poor, however, a moderate proportion of patients with isolated SCNS who received intensive therapies achieved durable remissions.
Journal ArticleDOI
R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma
Andrés J.M. Ferreri,Teresa Calimeri,Gian Marco Conte,Dario Cattaneo,Federico Fallanca,Maurilio Ponzoni,Eloise Scarano,Flavio Curnis,Alessandro Nonis,Paolo Lopedote,Giovanni Citterio,Letterio S. Politi,Marco Foppoli,Stefania Girlanda,Marianna Sassone,Salvatore Perrone,C. Cecchetti,Fabio Ciceri,Claudio Bordignon,Angelo Corti,Nicoletta Anzalone +20 more
TL;DR: In conclusion, NGR-hTNF/R-CHOP was safe in these heavily-pretreated patients and enhanced vascular permeability specifically in tumoral/peritumoral areas, which resulted in fast and sustained responses.
Journal ArticleDOI
Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial
Andrés J.M. Ferreri,Marianna Sassone,Francesco Zaja,Alessandro Re,Michele Spina,Alice Di Rocco,Alberto Fabbri,Caterina Stelitano,Maurizio Frezzato,Chiara Rusconi,Renato Zambello,Suzana Couto,Yan Ren,Annalisa Arcari,Giovanni Bertoldero,Alessandro Nonis,Lydia Scarfò,Teresa Calimeri,C. Cecchetti,Marianna Chiozzotto,Silvia Govi,Maurilio Ponzoni +21 more
TL;DR: This trial supports the use of lenalidomide maintenance in patients with chemo-sensitive relapse of DLBCL who are not eligible for ASCT or who had relapse after ASCT and the results warrant further investigation of immunomodulatory drugs as maintenance in high-risk patients withDLBCL.
Journal ArticleDOI
Clarithromycin as a "repurposing drug" against MALT lymphoma.
Andrés J.M. Ferreri,C. Cecchetti,Barbara Kiesewetter,Marianna Sassone,Teresa Calimeri,Salvatore Perrone,Maurilio Ponzoni,Markus Raderer +7 more
TL;DR: This study analysed 55 consecutive patients with MALT lymphoma and measurable/evaluable disease treated with clarithromycin monotherapy to establish activity (ORR) and efficacy (PFS) of clarithrocin treatment and establish the most tolerable and effective daily dose.
Journal ArticleDOI
Treatment of MALT lymphoma of the conjunctiva with intralesional rituximab supplemented with autologous serum
Andrés J.M. Ferreri,Marianna Sassone,Elisabetta Miserocchi,Silvia Govi,C. Cecchetti,Matteo E. Corti,Silvia Mappa,Luca Arcaini,Francesco Zaja,Giuseppe Todeschini,Donato Mannina,Teresa Calimeri,Salvatore Perrone,Maurilio Ponzoni,Giulio Modorati +14 more
TL;DR: In this article, the authors reported the first prospective phase 2 trial using intralesional rituximab supplemented with autologous serum in adults with relapsed/refractory indolent CD20+ lymphoma of the conjunctiva (NCT01514344).